Onychomycosis Therapy Market Trends and Forecast
The future of the global onychomycosis therapy market looks promising with opportunities in the general hospitals and specialty clinics markets. The global onychomycosis therapy market is expected to grow with a CAGR of 2.3% from 2025 to 2031. The major drivers for this market are the increased incidence of fungal infections and the topical antifungal treatments.
• Lucintel forecasts that, within the type category, drug therapy is expected to witness the highest growth over the forecast period due to the widespread use & accessibility.
• Within the application category, general hospitals is expected to witness the higher growth due to the comprehensive patient care and access to advanced treatment options.
• In terms of region, North America is expected to witness the highest growth over the forecast period.
Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below.
Emerging Trends in the Onychomycosis Therapy Market
The onychomycosis therapy market is evolving with various emerging trends that are changing how fungal infections are diagnosed and treated. These trends are driven by technological innovations, increased patient awareness, and shifting patient preferences for less invasive, more effective treatments.
• Rise of Non-Systemic Treatments: The trend towards non-systemic treatments is accelerating, with both topical antifungal agents and laser therapies gaining popularity. Topical treatments like efinaconazole and ciclopirox offer patients effective, less invasive options compared to oral drugs. Laser therapy, including fractional CO2 laser, provides a non-invasive, effective solution for patients with severe or resistant onychomycosis. These treatments offer reduced side effects and quicker recovery times, appealing to a growing number of patients seeking minimally invasive options. This shift represents a move towards more patient-friendly, localized therapies, improving overall treatment adherence.
• Focus on Personalized Medicine and Treatment Regimens: Personalized medicine is emerging as a significant trend in the onychomycosis therapy market. Advances in diagnostic tools, including genetic testing and microbiome analysis, are allowing clinicians to tailor treatment regimens to individual patients, improving treatment efficacy. Personalized approaches are particularly valuable in managing cases of onychomycosis that are resistant to standard therapies. This trend is expected to increase patient satisfaction and reduce relapse rates, offering a more customized and effective way of managing fungal infections.
• Increased Adoption of Laser Treatment Technologies: Laser therapy is gaining ground as a preferred treatment option for onychomycosis, especially in developed markets like the U.S., Japan, and Germany. Laser treatments, such as fractional CO2 laser and NDYAG lasers, have shown significant efficacy in targeting fungal infections in the nail bed. These technologies offer patients a non-invasive, pain-free alternative to oral medications and topical treatments, with fewer side effects. As laser technology becomes more accessible and affordable, its use is expected to expand globally, transforming the way onychomycosis is treated.
• Growth of Over-the-Counter (OTC) Treatments: The growth of over-the-counter antifungal treatments is a prominent trend in the onychomycosis therapy market, driven by rising patient awareness and self-care initiatives. OTC treatments, including antifungal nail lacquers and creams, are becoming increasingly popular, especially in emerging markets like India and China. These products are typically affordable and easy to use, making them an attractive option for patients with mild to moderate infections. The increasing availability of OTC treatments is expected to continue growing, offering a lower-cost alternative to prescription medications while contributing to higher treatment adherence.
• Increasing Focus on Preventative Measures: There is a growing focus on prevention in the onychomycosis therapy market. Preventative measures, such as antifungal foot and nail care products, are gaining popularity, particularly among people at high risk for onychomycosis, such as athletes or individuals with diabetes. These products aim to prevent fungal infections before they occur, reducing the need for costly and invasive treatments. Additionally, patient education campaigns are helping to raise awareness about the importance of proper foot hygiene, contributing to a preventative approach in managing onychomycosis.
The emerging trends in the onychomycosis therapy market ranging from non-systemic treatments to personalized regimens and laser technologies are reshaping the treatment landscape. These developments are offering patients more effective, convenient, and patient-friendly options, while also pushing for more preventative and accessible care. The market’s evolution points towards a more holistic approach to managing onychomycosis, with greater emphasis on both prevention and targeted therapies.
Recent Development in the Onychomycosis Therapy Market
Recent developments in the onychomycosis therapy market highlight key advancements in drug development, treatment modalities, and patient care. The market is seeing rapid growth, driven by new therapies, expanding access to care, and technological innovations that are changing the way fungal infections are treated.
• FDA Approval of New Topical Antifungal Treatments: New topical antifungal treatments, such as Efinaconazole, have gained FDA approval in recent years, offering patients a less invasive and more convenient option for treating onychomycosis. These topical solutions are easy to apply and are associated with fewer side effects compared to oral therapies, improving patient compliance. The approval of these treatments has been a significant development in the onychomycosis therapy market, expanding the range of effective therapeutic options available to patients.
• Growth of Laser Therapy as a Primary Treatment Option: Laser therapy has emerged as a key treatment modality for onychomycosis, gaining popularity due to its non-invasive nature and proven efficacy in clinical trials. Technologies like fractional CO2 lasers and NDYAG lasers are being increasingly adopted in clinical settings. Laser treatments provide a promising alternative to both oral and topical therapies, especially for patients with severe or resistant infections. As more clinical evidence supports the efficacy of laser therapy, its use is expected to rise globally, particularly in developed countries.
• Advancements in Oral Medications and Combination Therapies: Recent advancements in oral medications, such as Terbinafine and Iitraconazole, have improved the efficacy of onychomycosis treatment. In addition, combination therapies that combine oral antifungals with topical treatments are being explored to enhance treatment outcomes and reduce relapse rates. These innovations are aimed at improving the success rate of treatment, particularly for patients with chronic or resistant infections. The development of new oral therapies continues to play a crucial role in addressing the global burden of onychomycosis.
• Increasing Access to Over-the-Counter Treatments: There has been a significant increase in the availability of over-the-counter (OTC) antifungal treatments for onychomycosis, which has made treatment more accessible, especially in developing markets. Products such as antifungal creams, lacquers, and gels are now widely available at pharmacies without a prescription. This trend is particularly notable in emerging markets like India and China, where the affordability and convenience of OTC products are driving the growth of the onychomycosis treatment market.
• Enhanced Focus on Patient Education and Awareness: Patient education and awareness campaigns have become an important aspect of the onychomycosis therapy market. Increasing awareness about fungal infections, the importance of early diagnosis and proper nail care is helping to reduce the stigma associated with onychomycosis. As patients become more informed, they are more likely to seek treatment early, leading to better clinical outcomes and reduced transmission of the infection. Public health campaigns and educational resources are helping to expand the market by encouraging more people to address nail fungal infections promptly.
Recent developments in the onychomycosis therapy market, such as the approval of new topical and oral medications, the growth of laser therapies, the rise of OTC treatments, and increased patient education, are shaping a more effective and patient-friendly landscape for treating onychomycosis. These developments are driving market growth, improving patient outcomes, and making treatment more accessible worldwide.
Strategic Growth Opportunities in the Onychomycosis Therapy Market
The onychomycosis therapy market presents several strategic growth opportunities, particularly in emerging markets, new treatment modalities, and the increasing focus on prevention and patient care. These opportunities are set to drive the market’s expansion in the coming years.
• Expansion into Emerging Markets: Emerging markets, particularly in Asia and Africa, represent significant growth opportunities for onychomycosis therapy. As awareness of onychomycosis increases and healthcare infrastructure improves, the demand for effective treatments is rising. Manufacturers can expand their presence in these regions by offering affordable OTC treatments and partnering with local healthcare providers. The affordability and availability of generic medications will also play a crucial role in expanding the market in emerging economies.
• Development of New Topical Treatments: The demand for more effective, non-invasive treatments for onychomycosis is driving the development of new topical antifungal treatments. Companies can explore innovative formulations of topical agents that offer improved efficacy, reduced treatment duration, and fewer side effects. Topical treatments that are easier to apply and have a more rapid effect could become increasingly popular, providing an opportunity for growth in both developed and emerging markets.
• Investment in Laser Therapy: Laser therapy is a promising non-invasive treatment option for onychomycosis, and there is significant growth potential in this area. By investing in advanced laser technologies and expanding access to affordable laser treatments, healthcare providers can cater to patients seeking non-systemic options. The increasing clinical evidence supporting the effectiveness of laser therapy is expected to drive its adoption, particularly in developed countries where patients have higher purchasing power.
• Preventive Care and Education: Preventive care and education present another significant growth opportunity in the onychomycosis therapy market. By focusing on educating the public about foot hygiene, nail care, and early detection, companies can drive demand for over-the-counter antifungal treatments. Preventive products that help patients avoid onychomycosis in high-risk environments, such as gyms and swimming pools, will likely gain traction, expanding the scope of treatment offerings beyond therapy alone.
• Integration of Digital Tools for Diagnosis and Monitoring: The integration of digital health tools, including mobile apps for self-diagnosis and monitoring, offers a promising growth opportunity in the onychomycosis market. These tools can help improve patient engagement, monitor treatment progress, and reduce the risk of relapse. Companies that offer integrated solutions combining treatment with digital health platforms can capture a larger market share, especially in developed countries with tech-savvy populations.
The strategic growth opportunities in the onychomycosis therapy market lie in expanding access in emerging markets, developing new treatments, investing in laser therapy, focusing on prevention and education, and integrating digital tools. These opportunities are set to drive growth, improve patient outcomes, and reshape the market landscape.
Onychomycosis Therapy Market Driver and Challenges
The onychomycosis therapy market is influenced by several key drivers, such as technological advancements, rising awareness, and an increasing patient pool, as well as challenges related to affordability, market competition, and treatment efficacy.
The factors responsible for driving the onychomycosis therapy market include:
1. Increasing Prevalence of onychomycosis: The rising prevalence of onychomycosis, driven by factors such as aging populations, lifestyle changes, and climate, is a key driver of market growth. The condition is more common in individuals with diabetes, peripheral vascular disease, and immune suppression, all of which are on the rise globally. As more people are diagnosed, the demand for effective therapies increases.
2. Advancements in Treatment Modalities: Advancements in oral and topical antifungal treatments, as well as the growing adoption of laser therapies, are major drivers in the onychomycosis therapy market. New treatments with higher efficacy, fewer side effects, and quicker results are driving patient preference for advanced therapies. Laser technology is also offering patients a non-invasive treatment option with minimal downtime, contributing to market growth.
3. Increased Patient Awareness and Education: Patient awareness of onychomycosis is rising, especially with more emphasis on foot care and hygiene. As people become more informed about the symptoms and treatments available, they are more likely to seek timely medical attention. Educational campaigns, digital platforms, and social media are key factors in raising awareness, contributing to earlier diagnosis and treatment, which supports market growth.
4. Availability of Over-the-Counter Treatments: The growing availability of OTC treatments for onychomycosis is a significant market driver. These treatments are often more affordable and accessible than prescription options, enabling patients to treat mild cases independently. OTC antifungal products, such as creams and nail lacquers, are increasingly popular, particularly in developing markets, contributing to overall market expansion.
5. Focus on Prevention: The increasing focus on prevention, including antifungal hygiene products and patient education campaigns, is driving market growth. Preventive measures help reduce the incidence of onychomycosis, leading to lower treatment costs and better public health outcomes. The rise in preventive care creates new opportunities for growth, particularly for products designed to keep nails healthy and free from fungal infections.
Challenges in the onychomycosis therapy market are:
1. High Cost of Advanced Treatments: While innovations like laser therapy and combination treatments offer promising solutions, their high costs can limit their accessibility, particularly in low- and middle-income countries. Affordability remains a barrier for many patients, limiting access to effective therapies and preventing market growth in certain regions.
2. Regulatory Barriers and Delays: The regulatory approval process for new onychomycosis treatments can be lengthy and costly, slowing down the introduction of innovative products to the market. Companies must navigate complex regulatory environments in different regions, which can delay product launches and limit access to new therapies for patients.
3. Market Competition and Generic Substitutes: The onychomycosis therapy market is highly competitive, with numerous pharmaceutical companies offering similar products. The availability of generic drugs and OTC treatments also increases market competition, potentially reducing profit margins for new entrants. Companies need to differentiate their offerings through efficacy, safety, and patient convenience to maintain market share.
The onychomycosis therapy market is shaped by factors such as increasing prevalence, technological advancements, and heightened awareness, all of which drive growth. However, challenges such as high treatment costs, regulatory hurdles, and intense competition from generic drugs need to be overcome. These drivers and challenges will continue to influence the trajectory of the market in the coming years.
List of Onychomycosis Therapy Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies onychomycosis therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the onychomycosis therapy companies profiled in this report include-
• Bausch Health
• Bayer
• Cipla
• Dr Reddys Laboratories
• Galderma
• Johnson And Johnson
• Lumenis
• Medimetriks
• Moberg Pharma
• Novartis
Onychomycosis Therapy Market by Segment
The study includes a forecast for the global onychomycosis therapy market by type, application, and region.
Onychomycosis Therapy Market by Type [Value from 2019 to 2031]:
• Drug Therapy
• Laser Therapy
• Photodynamic Therapy
Onychomycosis Therapy Market by Application [Value from 2019 to 2031]:
• General Hospitals
• Specialty Clinics
Onychomycosis Therapy Market by Region [Value from 2019 to 2031]:
• North America
• Europe
• Asia Pacific
• The Rest of the World
Country Wise Outlook for the Onychomycosis Therapy Market
onychomycosis, a fungal infection of the nails, remains a significant concern worldwide, driving the demand for effective therapies. The onychomycosis therapy market has witnessed notable advancements over the past few years, particularly in the U.S., China, Germany, India, and Japan. These developments include the emergence of novel antifungal agents, improved drug delivery systems, and increased patient awareness. The market is evolving rapidly, with innovations in treatment options ranging from oral medications to topical solutions, laser therapies, and emerging combination treatments. The global market’s growth is fueled by better access to healthcare and the rising prevalence of fungal infections.
• United States: In the U.S., the onychomycosis therapy market has benefited from the FDA’s approval of new antifungal treatments, such as oral therapies (e.g., Terbinafine, Iitraconazole) and topical treatments (e.g., Efinaconazole). Laser treatments, including fractional CO2 laser therapy, have also gained traction, offering effective solutions for stubborn infections. Patient education on the condition has been a significant factor in increasing diagnosis rates. Additionally, innovative combination therapies are being explored to improve treatment efficacy, especially for cases resistant to traditional antifungal treatments. The U.S. market remains a leader in terms of both research and sales in the onychomycosis Therapy space.
• China: China has seen a rise in onychomycosis cases, driven by increasing urbanization, climate change, and improved diagnosis. The market is expanding with the introduction of both topical and oral antifungal treatments. Topical agents like ciclopirox and efinaconazole are gaining popularity due to their efficacy and reduced side effects compared to systemic treatments. There is also growing interest in the use of laser therapy as a non-invasive option for treating fungal nail infections. With increasing healthcare access and government-backed health initiatives, China’s onychomycosis therapy market is poised for significant growth, although affordability remains a key challenge in rural areas.
• Germany: Germany’s onychomycosis therapy market is characterized by high adoption rates of both pharmaceutical and non-pharmaceutical treatments. The regulatory environment in Germany is supportive, with timely approval for innovative therapies such as topical antifungal lacquers and laser treatments. Additionally, the country’s well-established healthcare infrastructure facilitates rapid access to treatment, and the increasing focus on dermatological care is driving demand for effective onychomycosis therapies. The German market is witnessing a growing preference for minimally invasive treatments, including laser therapy and the integration of digital health tools for better diagnosis and patient management.
• India: India is witnessing a surge in onychomycosis cases, largely due to climate, hygiene, and lifestyle factors. The market is driven by the increasing awareness of nail infections and the availability of over-the-counter antifungal treatments. While oral therapies remain the primary choice, topical treatments like nail lacquers are gaining popularity due to their ease of use. Additionally, the affordability of generic drugs is improving access to treatment, though affordability remains a challenge in rural areas. Laser therapy is still emerging in India but shows promise as a non-invasive option for severe cases, contributing to a growing, competitive market.
• Japan: Japan’s onychomycosis therapy market is experiencing steady growth, supported by an aging population that is more prone to fungal nail infections. The market is marked by high demand for both prescription medications and over-the-counter antifungal products. In Japan, laser therapies are becoming more widely adopted, with several new technologies being introduced. The regulatory environment is favorable, and the market is characterized by a combination of local and international companies offering treatments. The increasing prevalence of onychomycosis among elderly individuals is pushing the demand for more specialized treatments, including long-term, maintenance-focused therapies.
Features of the Global Onychomycosis Therapy Market
Market Size Estimates: Onychomycosis therapy market size estimation in terms of value ($M).
Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
Segmentation Analysis: Onychomycosis therapy market size by type, application, and region in terms of value ($M).
Regional Analysis: Onychomycosis therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the onychomycosis therapy market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the onychomycosis therapy market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the growth forecast for onychomycosis therapy market?
Answer: The global onychomycosis therapy market is expected to grow with a CAGR of 2.3% from 2025 to 2031.
Q2. What are the major drivers influencing the growth of the onychomycosis therapy market?
Answer: The major drivers for this market are the increased incidence of fungal infections and the topical antifungal treatments.
Q3. What are the major segments for onychomycosis therapy market?
Answer: The future of the onychomycosis therapy market looks promising with opportunities in the general hospitals and specialty clinics markets.
Q4. Who are the key onychomycosis therapy market companies?
Answer: Some of the key onychomycosis therapy companies are as follows:
• Bausch Health
• Bayer
• Cipla
• Dr Reddys Laboratories
• Galderma
• Johnson And Johnson
• Lumenis
• Medimetriks
• Moberg Pharma
• Novartis
Q5. Which onychomycosis therapy market segment will be the largest in future?
Answer: Lucintel forecasts that drug therapy is expected to witness the highest growth over the forecast period due to the widespread use & accessibility.
Q6. In onychomycosis therapy market, which region is expected to be the largest in next 5 years?
Answer: North America is expected to witness the highest growth over the forecast period.
Q7. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the onychomycosis therapy market by type (drug therapy, laser therapy, and photodynamic therapy), application (general hospitals and specialty clinics), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Onychomycosis Therapy Market, Onychomycosis Therapy Market Size, Onychomycosis Therapy Market Growth, Onychomycosis Therapy Market Analysis, Onychomycosis Therapy Market Report, Onychomycosis Therapy Market Share, Onychomycosis Therapy Market Trends, Onychomycosis Therapy Market Forecast, Onychomycosis Therapy Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.